Jefferies analyst Raj Denhoy reiterated a Buy rating on Abbott Labs (NYSE: ABT) on October 17 and set a price target of $80. The company’s shares closed on Friday at $67.59.
According to TipRanks.com, Denhoy is a top 25 analyst with an average return of 19.9% and a 70.8% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Edwards Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Labs with a $78.80 average price target, a 16.6% upside from current levels. In a report issued on October 15, Barclays also initiated coverage with a Buy rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.15 and a one-year low of $53.61. Currently, Abbott Labs has an average volume of 5.76M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
